Erowid References Database
|
DALY J, AXELROD J, WITKOP B.
“Methylation and demethylation in relation to the in vitro metabolism of mescaline”.
Ann N Y Acad Sci. 1962 Jan 01;96:37-43.
|
|
Abstract
The actions of the hallucinogenic drug mescaline have been explained as due to the formation of an active metabolite, or to the induction of a formation of a hallucinogenic substance, or to be caused by interference with the detoxification of naturally formed hallucinogens. In vivo studies on the metabolism of mescaline have shown that a large part of the mescaline combines with liver protein and that varying amounts are excreted unchanged or as the oxidatively deaminated product, 3,4,5-trimethoxyphenylacetic acid. Certain minor metabolites have also been identified. Harley-Mason has isolated 3,4-
dihydroxy-5-methoxyphenylacetic acid from human urine after the ingestion of mescaline, while Ratcliffe and Smith have found 3,4-dimethoxy-S-hydroxyphenethylamine 111 as a minor metabolite of mescaline in humans. Goldstein et al. have reported 3,4, 5-trimethoxyphenylethanol as a mescaline metabolite in rats.
|
| # |
| Submit Comment |
|
[
Cite HTML ]
